Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Financial Lp Hrt Acquires 25,836 Shares

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt acquired 25,836 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were bought at an average price of $3.44 per share, with a total value of $88,875.84. Following the acquisition, the insider directly owned 71,842 shares of the company’s stock, valued at $247,136.48. The trade was a 56.16% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, June 30th, Financial Lp Hrt bought 6,755 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average price of $3.23 per share, for a total transaction of $21,818.65.

Shuttle Pharmaceuticals Price Performance

Shares of Shuttle Pharmaceuticals stock traded up $0.15 on Wednesday, reaching $3.40. 169,219 shares of the company traded hands, compared to its average volume of 2,351,062. Shuttle Pharmaceuticals Holdings, Inc. has a 52 week low of $2.90 and a 52 week high of $55.90. The company has a 50 day moving average of $5.93 and a 200 day moving average of $10.74. The firm has a market capitalization of $2.18 million, a PE ratio of -0.07 and a beta of 0.29.

Shuttle Pharmaceuticals (NASDAQ:SHPH) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.60 EPS for the quarter.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in SHPH. Geode Capital Management LLC purchased a new position in Shuttle Pharmaceuticals in the 4th quarter worth $26,000. Boothbay Fund Management LLC purchased a new stake in Shuttle Pharmaceuticals during the fourth quarter valued at about $37,000. Ikarian Capital LLC purchased a new stake in Shuttle Pharmaceuticals during the fourth quarter valued at about $124,000. Finally, Connective Capital Management LLC bought a new position in shares of Shuttle Pharmaceuticals during the third quarter valued at about $357,000. Institutional investors own 4.58% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

About Shuttle Pharmaceuticals

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .